| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.01 M USD | -2.97 M USD | -4.76 M USD | -6.60 M USD | -6.03 M USD | -4.78 M USD | 1.37 M USD | -652971 USD | -181270 USD | -323900 USD | -151622 USD | -19401 USD |
| Depreciation & Amortization | 677364 USD | 919603 USD | 200894 USD | 77301 USD | 27760 USD | 11917 USD | 10788 USD | 5190 USD | 2810 USD | 1878 USD | 5633 USD | 10531 USD |
| Stock-Based Compensation | 162920 USD | — | — | 1.62 M USD | 1.54 M USD | 1.14 M USD | 69787 USD | 0 USD | — | — | — | — |
| Capital Expenditures | 43412 USD | 183703 USD | 444722 USD | 10785 USD | 415710 USD | 49261 USD | 64839 USD | 19400 USD | 0 USD | 15700 USD | 0 USD | — |
| Cash Flow from Investing | -2.75 M USD | 363895 USD | -2.49 M USD | -81217 USD | -2.15 M USD | -187254 USD | -114706 USD | -19400 USD | 0 USD | -15700 USD | 0 USD | — |
| Cash Flow from Financing | 11.10 M USD | 3.12 M USD | 7.39 M USD | 1.09 M USD | 3.77 M USD | 13.82 M USD | -229465 USD | 858855 USD | 54625 USD | 0 USD | 625000 USD | 20000 USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -7.06 M USD | -3.16 M USD | -5.20 M USD | -6.61 M USD | -6.45 M USD | -4.82 M USD | 1.31 M USD | -672371 USD | -181270 USD | -339600 USD | -151622 USD | — |
INVO Fertility, Inc. is a healthcare services company focused on the fertility market, providing assisted reproductive technology care through innovative clinic operations and medical devices. It operates fertility clinics, including branded INVO Centers dedicated primarily to the intravaginal culture procedure enabled by its proprietary INVOcell device, as well as traditional in vitro fertilization clinics. The INVOcell is a medical device that facilitates fertilization and early embryo development in vivo within the woman's body, offering an alternative to conventional lab-based methods. The company also sells and distributes the INVOcell device to third-party fertility clinics. Its services encompass a range of reproductive options such as IVF, intravaginal culture, intrauterine insemination, fertility preservation, and advanced diagnostic testing. INVO Fertility, Inc. maintains a network of operational clinics in the United States and pursues acquisitions to expand its platform. Founded in 2007 and headquartered in Sarasota, Florida, it plays a role in making fertility treatments more accessible in the healthcare sector.